Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial

Solidarity Finland Investigators, Alex L.E. Halme, Sanna Laakkonen, Jarno Rutanen, Olli P.O. Nevalainen, Marjatta Sinisalo, Saana Horstia, Jussi M.J. Mustonen, Negar Pourjamal, Aija Vanhanen, Tuomas Rosberg, Andreas Renner, Markus Perola, Erja Leena Paukkeri, Riitta Liisa Patovirta, Seppo Parkkila, Juuso Paajanen, Taina Nykänen, Jarkko Mäntylä, Marjukka MyllärniemiTiina Mattila, Maarit K. Leinonen, Alvar Külmäsu, Pauliina Kuutti, Ilari Kuitunen, Hanna Riikka Kreivi, Tuomas P. Kilpeläinen, Heikki Kauma, Ilkka E.J. Kalliala, Petrus Järvinen, Riina Hankkio, Taina Hammarén, Thijs Feuth, Hanna Ansakorpi, Riikka Ala-Karvia, Gordon H. Guyatt, Kari A.O. Tikkinen

Tutkimustuotos: ArtikkeliTieteellinenvertaisarvioitu

2 Sitaatiot (Scopus)
21 Lataukset (Pure)

Abstrakti

Objectives: We studied the short- and long-term effects of imatinib in hospitalized COVID-19 patients. Methods: Participants were randomized to receive standard of care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of randomized trials studying imatinib for 30-day mortality in hospitalized COVID-19 patients. Results: We randomized 156 patients (73 in SoC and 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year, and in SoC, 4.1% and 8.2% (adjusted HR 1.35, 95% CI 0.47–3.90). At 1 year, self-reported recovery occurred in 79.0% in imatinib and in 88.5% in SoC (RR 0.91, 0.78–1.06). We found no convincing difference in quality of life or symptoms. Fatigue (24%) and sleep issues (20%) frequently bothered patients at one year. In the meta-analysis, imatinib was associated with a mortality risk ratio of 0.73 (0.32–1.63; low certainty evidence). Conclusions: The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalized COVID-19 patients.

AlkuperäiskieliEnglanti
Artikkeli106217
JulkaisuJOURNAL OF INFECTION
Vuosikerta89
Numero3
DOI - pysyväislinkit
TilaJulkaistu - syysk. 2024
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 2

!!ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Sormenjälki

Sukella tutkimusaiheisiin 'Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä